LATEST
Introducing the Rayove Watch: Smartwatch Featuring Online AI Translation in 73 Languages and Camera-Based OCR TranslationPathogenDx Announces Five-Year Cooperative Research and Development Agreement with USDA Agricultural Research Service to Advance Rapid Detection of High-Pathogenicity SalmonellaA $16.5M Pikachu Illustrator Leads 525 Six-Figure Pokémon Card SalesChancellor Urged to Back UK Research with Budget Package Worth £50bn to UK Output‘We Can’t Hide’: Israel-Backed Militias Bring Night Raids and Fear to Gaza’s Displaced FamiliesWarpWare Closes Oversubscribed Pre-Seed Round to Expand Agentic Engineering Capabilities for Space MissionsGaza Faces Deeper Hunger as Food Aid Is Cut and Israel Halts Commercial Shipments‘Who Among You Would Accept These Terms?’ Palestine Confronts UN Over Gaza’s Dead and the Demand for Endless SubmissionGaza’s Hunger Crisis Gives New Urgency to French Case Against Aid-Blocking ActivistsSnowden: Western Governments Arming Israel’s Gaza Campaign Are ‘Most Probably’ Acting CriminallyIntroducing the Rayove Watch: Smartwatch Featuring Online AI Translation in 73 Languages and Camera-Based OCR TranslationPathogenDx Announces Five-Year Cooperative Research and Development Agreement with USDA Agricultural Research Service to Advance Rapid Detection of High-Pathogenicity SalmonellaA $16.5M Pikachu Illustrator Leads 525 Six-Figure Pokémon Card SalesChancellor Urged to Back UK Research with Budget Package Worth £50bn to UK Output‘We Can’t Hide’: Israel-Backed Militias Bring Night Raids and Fear to Gaza’s Displaced FamiliesWarpWare Closes Oversubscribed Pre-Seed Round to Expand Agentic Engineering Capabilities for Space MissionsGaza Faces Deeper Hunger as Food Aid Is Cut and Israel Halts Commercial Shipments‘Who Among You Would Accept These Terms?’ Palestine Confronts UN Over Gaza’s Dead and the Demand for Endless SubmissionGaza’s Hunger Crisis Gives New Urgency to French Case Against Aid-Blocking ActivistsSnowden: Western Governments Arming Israel’s Gaza Campaign Are ‘Most Probably’ Acting Criminally
Business

Diabeloop Unveils New DBLG2 Demo App: Experience the Future of Automated Insulin Delivery Simulation

Richard Powell  2 min read

Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is an interactive simulation and a preview of the virtual DBLG2 System.

Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is an interactive simulation and a preview of the virtual DBLG2 System.

Initially launching exclusively on the Google Play Store in Germany and the Netherlands, this new simulation tool allows anyone to explore the ecosystem on their own smartphone. The first version available is DBLG2 with a virtual Kaleido insulin pump. Other virtual pumps will be available soon. To use it, you simply need an Android smartphone running on Android 13 or higher.

A Complete, Risk-Free Simulation Experience

The new DBLG2 Demo app simulates interaction with the system and provides an overview of the many features and benefits of DBLG2 System. Users can seamlessly navigate through the app’s four screens (Home, Events, System, Profile) and see the various features available.

Through a highly intuitive onboarding process, users can experience the daily management of DBLG2 system through several simulated features:

  • Virtual Device Pairing: From the System screen, users can follow the steps to pair a Demo CGM (Continuous Glucose Monitoring). The CGM pairing allows simulated glucose data to be displayed. Steps are also available to pair a virtual insulin pump. It will allow the user to access the simulated pump features.
  • Interactive Loop Mode Toggle: Users can explore the Home screen and activate the loop mode button to see how the system displays its active status.
  • Comprehensive Event Management: Enabling loop mode allows users to simulate features such as meal declarations. A dedicated button lets users add events such as a Pen bolus, Pump bolus, Rescue carbs, Physical activity, and Meals.
  • Custom Demo Menu: A specific demo menu (which does not exist in the actual DBLG2 app) allows users to choose their virtual glucose profile and trigger simulated alarms, alerts, or information messages and reset the app to restart initialization.

Important Safety Information

While the DBLG2 Demo app provides a realistic user experience, Diabeloop emphasizes that the DBLG2 Demo app is not a medical device.

  • This application is for demonstration and training purposes only.
  • It must not be used to make therapeutic decisions.
  • Users cannot pair a real device to the app.

The actual Diabeloop algorithm is not integrated – only a few functions are simulated to demonstrate some of its features.

Beyond the DBLG2 Demo app, what about DBLG2 availability ?

  • DBLG2 System availability varies by country and insulin pump partners.
  • DBLG2 is available with Kaleido (ViCentra) and soon, with DANA-i (SOOIL).

For questions on availability, please refer to your distributor. For specifics on indications and therapeutic decisions, users and healthcare professionals should refer to the official user guide.

Founded in 2015, Diabeloop develops AI-based solutions to help people living with diabetes automate and personalize their treatment. By connecting CGMs and insulin pumps through proprietary self-learning algorithms, Diabeloop enables users to delegate therapeutic decisions and live with fewer daily interruptions. — diabeloop.com

Related articles

Top